Sugi Predict

Sugi Predict / Compounds / SCHEMBL7513614

SCHEMBL7513614

SCHEMBL7513614

Cc1[nH]c2ncc(Br)cc2c1I

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 2/20 0.45
▸ DYRK1A Q13627 7/20 0.42
▸ AURKA O14965 3/20 0.42
▸ JAK2 O60674 3/20 0.42
▸ MAP4K4 O95819 3/20 0.42
▸ FGFR1 P11362 3/20 0.42
▸ FLT1 P17948 3/20 0.42
▸ KDR P35968 3/20 0.42
▸ CLK2 P49760 3/20 0.42
▸ CDK5 Q00535 3/20 0.42
▸ MAP4K2 Q12851 3/20 0.42
▸ AURKB Q96GD4 3/20 0.42
▸ CLK4 Q9HAZ1 3/20 0.42
▸ PRKD3 O94806 2/20 0.42
▸ TAOK1 Q7L7X3 2/20 0.42
▸ IGF1R P08069 2/20 0.42
▸ JAK3 P52333 2/20 0.42
▸ LIMK1 P53667 2/20 0.42
▸ NTRK2 Q16620 2/20 0.42
▸ PLK4 O00444 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30280407 1.00 CHEK1 (0.45) CHEK1DYRK1AAURKAJAK2MAP4K4
SCHEMBL1565081 0.85 CHEK1 (0.45) CHEK1DYRK1AAURKAJAK2MAP4K4
SCHEMBL21417550 0.81 CHEK1 (0.43) CHEK1DYRK1AAURKAJAK2MAP4K4
SCHEMBL25153315 0.79 CHEK1 (0.44) CHEK1DYRK1AAURKAJAK2MAP4K4
SCHEMBL30280432 0.79 CHEK1 (0.44) CHEK1DYRK1AAURKAJAK2MAP4K4
SCHEMBL25153268 0.79 CHEK1 (0.41) CHEK1DYRK1AAURKAJAK2MAP4K4
SCHEMBL30280374 0.79 CHEK1 (0.41) CHEK1DYRK1AAURKAJAK2MAP4K4
SCHEMBL23101646 0.78 MAP4K1 (0.46) CHEK1DYRK1AAURKAJAK2MAP4K4
SCHEMBL25153601 0.75 DYRK1B (0.41) CHEK1DYRK1AAURKAJAK2MAP4K4
SCHEMBL25153336 0.75 KDM4E (0.45) CHEK1DYRK1AAURKAJAK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425499-A1 TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2024-12-26 — — US disclosed
WO-2023064218-A1 TYRO3 INHIBITORS Halia Therapeutics, Inc. (US) 2023-04-20 — — WO disclosed
WO-2023064218-A1 TYRO3 INHIBITORS Halia Therapeutics, Inc. (US) 2023-04-20 — — WO disclosed
EP-3545956-B1 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H- PYRROLO[2,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS ARRIEN PHARMACEUTICALS LLC (US) 2020-12-16 — — EP disclosed
EP-3545956-A1 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H- PYRROLO[2,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS Arrien Pharmaceuticals LLC (US) 2019-10-02 — — EP disclosed
EP-2925319-B1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES UNIV ROCHESTER (US) 2019-01-09 — — EP disclosed
EP-2925319-B1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES UNIV ROCHESTER (US) 2019-01-09 — — EP disclosed
WO-2016026078-A1 HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) 2016-02-25 — — WO disclosed
US-20150297587-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-22 — — US disclosed
US-20150297587-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-22 — — US disclosed
EP-2925319-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES University Of Rochester (US) 2015-10-07 — — EP disclosed
US-8846909-B2 Bicyclic heteroaryl kinase inhibitors and methods of use UNIVERSITY OF ROCHESTER (US) 2014-09-30 — — US disclosed
US-8846909-B2 Bicyclic heteroaryl kinase inhibitors and methods of use UNIVERSITY OF ROCHESTER (US) 2014-09-30 — — US disclosed
WO-2014085795-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES UNIVERSITY OF ROCHESTER (US) 2014-06-05 — — WO disclosed
WO-2014085795-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES UNIVERSITY OF ROCHESTER (US) 2014-06-05 — — WO disclosed
US-20130203755-A1 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE UNIVERSITY OF ROCHESTER (US) 2013-08-08 — — US disclosed
US-20130203755-A1 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE UNIVERSITY OF ROCHESTER (US) 2013-08-08 — — US disclosed
EP-2576549-A2 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE University of Rochester (US) 2013-04-10 — — EP disclosed
WO-2011149950-A2 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE UNIVERSITY OF ROCHESTER (US) 2011-12-01 — — WO disclosed
WO-2011149950-A2 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE UNIVERSITY OF ROCHESTER (US) 2011-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297587-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES MLKL, MARCKS, MAP3K4 CHEK1 263/4885DYRK1A 976/4885AURKA 385/4885
US-20240425499-A1 TYRO3 INHIBITORS TYRO3, TYR, TH CHEK1 3068/4885DYRK1A 20/4885AURKA 1990/4885
US-20130203755-A1 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE MAP2K2, MAP2K7, CHKB CHEK1 173/4885DYRK1A 349/4885AURKA 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.